2023年7月25日

研究数据显示公司的呼吸反应声音生物标记工具区别从健康个体患者呼吸状况。总经理迈克尔Barbella Editor07.25.23探头健康是共享的新研究表明呼吸道反应的生物标志物的能力(RRVB)机器学习模型COVID-19患者与健康人有70%的准确率。同行评议的研究,发表在《医学互联网研究(JMIR),建议RRVB工具可以作为急性呼吸道感染和预审工具为语音的发展铺平道路未来疾病检测和监视应用程序的工具。RRVB工具已经强劲性能区分患者哮喘、慢性阻塞性肺疾病(COPD)、间质性肺疾病,从健康个体和咳嗽。在新的研究中,进行了与蒙蒂菲奥里医疗体系合作,布莱根妇女医院,加州大学圣地亚哥分校卫生系统,和Deenanath Mangeshkar医院在浦那(印度、模型实现为整个COVID-19敏感性73%,特异性63%人口(97例),并发现66%的无症状COVID-19科目(46例)只使用一个六秒钟记录一个“啊”元音病人智能手机。这些发现表明,工具可以帮助发现呼吸道疾病在症状出现之前。“我们已经表明,相同的技术最初开发哮喘和慢性阻塞性肺病可用于筛选与有意义的敏感性和特异性,COVID-19“探头健康临床开发的高级副总裁&客户成功埃里克·拉森说。“这项研究表明我们的工具的健壮性条件,地域,语言,为更广泛的呼吸道疾病铺平了道路监控和监测工作。招收了497名研究参与者在四个临床基地在美国和印度,包括患者COVID-19阳性,其他急性疾病患者和无症状志愿者没有急性疾病的研究。Sunit博士Jariwala,医学博士, professor of Medicine and director of Clinical Research and Innovation in the Department of Medicine at Einstein College of Medicine and Montefiore Health System, served as principal investigator for the study. "This study highlights the potential of vocal biomarkers to improve access and outcomes for diverse and varied populations with respiratory diseases,” he stated. “By utilizing a digital tool that is non-invasive and can be easily scaled and distributed, we can effectively monitor respiratory health and identify individuals’ levels of symptoms and risk. Based on the promising results from this study, we are working with Sonde Health to study the RRVB tool for respiratory monitoring in patients with moderate-to-severe asthma, and we are at the beginning stages of an Agency for Healthcare Research and Quality (AHRQ)-funded study to incorporate the RRVB tool into our own ASTHMAXcelmobile platform.” The RRVB tool was originally developed and tested using a diverse dataset that included more than 3,000 patients with respiratory conditions, including asthma, COPD, and interstitial lung disease, as well as healthy individuals. The data was collected from more than 20 hospitals across India between August 2018 and January 2020 and encompassed multiple languages. The COVID-19 validation study tested this tool for its ability to differentiate patients with COVID-19 from healthy individuals with data collected from September 2020 through April 2021. Sonde Health develops voice-based health monitoring technology. Sonde serves top health companies, providers, pharmaceutical, and device OEMs through its vocal biomarker platform. Leveraging a best-in-class voice data set with more than 1.2 million samples from 85,000-plus individuals on four continents, Sonde uses advanced audio signal processing, speech science, and AI/machine learning to sense and analyze subtle vocal changes due to changes in a person’s physiology to provide key insights into health and well-being. Trending